{
  "source": "PA-Med-Nec-Cinryze.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2031-15\nProgram Prior Authorization/Medical Necessity\nMedication Cinryze® (C1 esterase inhibitor, human)*\n* Cinryze is excluded from coverage for the majority of our benefits\nP&T Approval Date 8/2014, 8/2015, 7/2016, 7/2017, 7/2018, 7/2019, 6/2020, 3/2021,\n3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nCinryze is a plasma-derived C1 esterase inhibitor (human) indicated for routine prophylaxis\nagainst angioedema attacks in adolescent, adult, and pediatric (6 years of age and above)\npatients with hereditary angioedema (HAE).1\n2. Coverage Criteria a:\nA. Initial Authorization\n1. Cinryze will be approved based on all of the following criteria:\na. Diagnosis of hereditary angioedema (HAE) as confirmed by one of the following:\n(1) C1 inhibitor (C1-INH) deficiency or dysfunction (Type I or II HAE) as\ndocumented by one of the following (per laboratory standard):\n(a) C1-INH antigenic level below the lower limit of normal\n(b) C1-INH functional level below the lower limit of normal\n-OR-\n(2) HAE with normal C1 inhibitor levels and one of the following:\n(a) Confirmed presence of variant(s) in the gene(s) for factor XII, angiopoietin-1,\nplasminogen-1, kininogen-1, myoferlin, and heparan sulfate-glucosamine 3-\nO-sulfotransferase 6\n(b) Recurring angioedema attacks that are refractory to high-dose antihistamines\nwith confirmed family history of angioedema\n(c) Recurring angioedema attacks that are refractory to high-dose antihistamines\nwith unknown background de-novo mutation(s) (i.e., no family history)\n(HAE-unknown)\n-AND-\nb. All of the following:\n(1) Prescribed for the prophylaxis of HAE attacks\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Not used in combination with other products indicated for prophylaxis against\nHAE attacks (e.g., Haegarda, Orladeyo, Takhzyro)\n-AND-\n(3) Prescriber attests that patient has experienced attacks of a severity and/or\nfrequency such that they would c",
    "dicated for prophylaxis against\nHAE attacks (e.g., Haegarda, Orladeyo, Takhzyro)\n-AND-\n(3) Prescriber attests that patient has experienced attacks of a severity and/or\nfrequency such that they would clinically benefit from prophylactic therapy with\nCinryze\n-AND-\nc. History of failure to both of the following (document date of trial and list reason for\ntherapeutic failure):\n(1) Haegarda (C1 esterase inhibitor, human)\n(2) Takhzyro (lanadelumab)\n-AND-\nd. Prescribed by one of the following:\n(1) Immunologist\n(2) Allergist\nAuthorization of therapy will be issued for 12 months.\nB. Reauthorization\n1. Cinryze will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Cinryze therapy.\n-AND-\nb. Reduction in the utilization of on-demand therapies used for acute attacks (e.g.,\nBerinert, Firazyr, Ruconest) as determined by claims information, while on Cinryze\ntherapy\n-AND-\nc. Both of the following:\n(1) Prescribed for the prophylaxis of HAE attacks\n-AND-\n(2) Not used in combination with other products indicated for prophylaxis against\n© 2025 UnitedHealthcare Services, Inc.\n2\nHAE attacks (e.g., Haegarda, Orladeyo, Takhzyro)\n-AND-\nd. Prescribed by one of the following:\n(1) Immunologist\n(2) Allergist\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cinryze [package insert]. Lexington, MA: ViroPharma Biologics LLC ; November 2024.\n2. Maurer M, Magerl M, Ansotegui ",
    "rogram\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cinryze [package insert]. Lexington, MA: ViroPharma Biologics LLC ; November 2024.\n2. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the\nmanagement of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Jan 10.\n3. Wu, E. Hereditary angioedema with normal C1 inhibitor. In: UpToDate, Saini, S (Ed),\nUpToDate, Waltham, MA, 2023.\n4. Busse, P., Christiansen, S., Riedl, M., et. al. “US HAEA Medical Advisory Board 2020\nGuidelines for the Management of Hereditary Angioedema.” The Journal of Allergy and\nClinical Immunology. 2020 September 05.\n5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the\nmanagement of hereditary angioedema-The 2021 revision and update. Allergy.\n2022;77(7):1961-1990. doi:10.1111/all.15214\nProgram Prior Authorization/Medical Necessity - Cinryze (C1 esterase inhibitor,\nhuman)\nChange Control\n8/2014 New program.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n8/2015 Annual review. No change.\n7/2016 Annual review with no changes to the coverage criteria. Updated\nbackground and references. Added Maryland, Indiana and West\nVirginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n© 2025 UnitedHealthcare Services, Inc.\n3\n2/2017 Administrative change. Correct Oxford effective date.\n7/2017 Annual review. No change to criteria. Updated reference.\n7/2018 Annual review. Updated coverage criteria. Updated references.\n7/2019 Annual review. Updated background and references.\n6/2020 Annual review. Aligned criteria with acute and prophylactic therapies.\nRemoved off-label use for acute attacks. Added notation that Cinryze is\nexcluded for most plans.\n3/2021 Added diagnosis criteria and aligned combination use language with\nprophylactic therapies. Updated references.\n3/2022 Annual review. Updated references.\n3/2023 Annual review",
    "ded for most plans.\n3/2021 Added diagnosis criteria and aligned combination use language with\nprophylactic therapies. Updated references.\n3/2022 Annual review. Updated references.\n3/2023 Annual review. Updated references.\n3/2024 Annual review with update to diagnostic criteria for HAE with normal\nC1 inhibitor levels. Simplified reauthorization criteria. Updated\nreference.\n3/2025 Annual review. Updated coverage criteria by adding Takhzyro\n(lanadelumab) to list of products requiring a history of use. Updated\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}